MaxCyte, Inc. Files 8-K for Financials and Reg FD
Ticker: MXCT · Form: 8-K · Filed: Jan 30, 2025 · CIK: 1287098
Sentiment: neutral
Topics: financials, regulation-fd
Related Tickers: MXCT
TL;DR
MaxCyte filed an 8-K on Jan 30, 2025, for financials and Reg FD. Details TBD.
AI Summary
MaxCyte, Inc. filed an 8-K on January 30, 2025, to report on financial statements and exhibits, as well as a Regulation FD disclosure. The filing does not contain specific financial figures or details about the nature of the Regulation FD disclosure.
Why It Matters
This 8-K filing indicates MaxCyte, Inc. is providing updated financial information and potentially making a disclosure under Regulation FD, which could impact investor understanding of the company's current status.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for financial reporting and Regulation FD disclosure, with no immediate indication of significant negative events.
Key Players & Entities
- MaxCyte, Inc. (company) — Registrant
- January 30, 2025 (date) — Filing Date
FAQ
What specific financial statements are being filed with this 8-K?
The filing indicates that financial statements and exhibits are being provided, but the specific details of these statements are not included in the provided text.
What is the subject of the Regulation FD disclosure mentioned in the filing?
The filing states that a Regulation FD Disclosure is being made, but the specific topic of this disclosure is not detailed in the provided text.
What is MaxCyte, Inc.'s principal executive office address?
MaxCyte, Inc.'s principal executive offices are located at 9713 Key West Avenue, Suite 400, Rockville, Maryland 20850.
What is MaxCyte, Inc.'s telephone number?
MaxCyte, Inc.'s telephone number is (301) 944-1700.
When was MaxCyte, Inc. incorporated?
MaxCyte, Inc. was incorporated in Delaware.
Filing Stats: 523 words · 2 min read · ~2 pages · Grade level 12.2 · Accepted 2025-01-30 07:30:11
Key Financial Figures
- $0.01 — ge on which registered Common Stock, $0.01 par value MXCT The Nasdaq Stock Mar
Filing Documents
- mxct-20250130x8k.htm (8-K) — 37KB
- mxct-20250130xex99d1.htm (EX-99.1) — 23KB
- mxct-20250130xex99d1001.jpg (GRAPHIC) — 4KB
- mxct-20250130xex99d1002.jpg (GRAPHIC) — 6KB
- 0001558370-25-000526.txt ( ) — 201KB
- mxct-20250130.xsd (EX-101.SCH) — 3KB
- mxct-20250130_lab.xml (EX-101.LAB) — 16KB
- mxct-20250130_pre.xml (EX-101.PRE) — 10KB
- mxct-20250130x8k_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On January 30, 2025, MaxCyte, Inc., a Delaware corporation (the "Company") issued a press release announcing its acquisition of SeQure DX Inc., a Delaware corporation ("SeQure"), a market leader of on-target and off-target editing assessment services for cell and gene therapies. A copy of the press release is attached hereto as Exhibit 99.1. The information contained in this Current Report on Form 8-K, including Exhibit 99.1 hereto, is being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. .
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Press Release, dated January 30, 2025 104 Cover Page Interactive Data (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MaxCyte, Inc. Dated: January 30, 2025 By: /s/ Douglas Swirsky Douglas Swirsky Chief Financial Officer